<code id='579FEA179F'></code><style id='579FEA179F'></style>
    • <acronym id='579FEA179F'></acronym>
      <center id='579FEA179F'><center id='579FEA179F'><tfoot id='579FEA179F'></tfoot></center><abbr id='579FEA179F'><dir id='579FEA179F'><tfoot id='579FEA179F'></tfoot><noframes id='579FEA179F'>

    • <optgroup id='579FEA179F'><strike id='579FEA179F'><sup id='579FEA179F'></sup></strike><code id='579FEA179F'></code></optgroup>
        1. <b id='579FEA179F'><label id='579FEA179F'><select id='579FEA179F'><dt id='579FEA179F'><span id='579FEA179F'></span></dt></select></label></b><u id='579FEA179F'></u>
          <i id='579FEA179F'><strike id='579FEA179F'><tt id='579FEA179F'><pre id='579FEA179F'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:9
          Johnson & Johnson logo. -- health coverage from STAT.
          Chris O'Meara/AP

          Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

          Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

          advertisement

          In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more
          FDA approves first treatment for ultra
          FDA approves first treatment for ultra

          AdobeU.S.regulatorsonWednesdayapprovedthefirsttreatmentforanultra-rarediseasethatcausespeopletogrowb

          read more
          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more

          Buoyed by wins on obesity, Novo Nordisk eyes heart disease

          AdobePHILADELPHIA—NovoNordisk,whichhasdominatedthediabetesandobesitymarketswithitsblockbusterdrugsOz